Bibliografia

Adams RL, Adams IP, Lindow SW, Zhong W, Atkin SL (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493-1498

Adams RL, Adams IP, Lindow SW, Atkin SL (2004) Inhibition of endothelial proliferation by the somatostatin analogue SOM230. Clin Endocrinol (Oxf) 61:431-436

Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, Thellung S, Cai T, Noonan DM, Schettini G (1999) Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 13:647-655

Afargan M, Janson E. , Gelerman G, Rakefet Rosenfeld, Offer Ziv, Olga Karpov, Amnon Wolf, Moshe Bracha, Dvira Shohat, George Liapakis, Chaim Gilon, Amnon Hoffman, David Stephensky and Kjell Oberg. (2001) Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin Endocrinology 142: 477-486

Alderton F, Humphrey PP, Sellers LA (2001) High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors. Mol Pharmacol 59:1119-1128

Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:993-997

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275(5302):964-7.

Avouac J, Wipff J, Goldman O, Ruiz B, Couraud PO, Chiocchia G, Kahan A, Boileau C, Uzan G,Allanore Y (2008) Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum 58:3550-3561

Barnett P. (2003) Somatostatin and somatostatin receptor physiology. Endocrine. 20(3):255-64.

Bartoli M, Al-Shabrawey M, Labazi M, Behzadian MA, Istanboli M, El-Remessy AB, Caldwell RW, Marcus DM, Caldwell RB. (2009). HMG-CoA reductase inhibitors (statin) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 50:4934-40.

Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks SE, Marrero MB, Caldwell RB (2003). VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. (11):1562-4.

Battegay EJ. (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med.73:333-46

Bernatchez PN, Rollin S, Soker S, Sirois MG. (2002) Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem.;85(3):629-39.

Benelli R, Morini M, Brigati C, Noonan DM, Albini A (2003). Angiostatin inhibits extracellular HIV-Tat-induced inflammatory angiogenesis.Int J Oncol. 22(1):87-91.

Bocci G, Culler MD, Fioravanti A, Orlandi P, Fasciani A, Colucci R, Taylor JE, Sadat D, Danesi R, Del Tacca M (2007) *In vitro* antiangiogenic activity of selective somatostatin subtype-1 receptor agonists. Eur J Clin 37:700-708

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254

Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 179(68):77-9.

Cao Y. (2001) Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol.33:357-69.

Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. (2001). Synergism between vascular endothelial

growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 7:575-83.

Carmeliet P, Jain RK. (2000) Angiogenesis in cancer and other diseases. Nature. 407:249-57.

Casini G, Catalani E, Dal Monte M, Bagnoli P. (2005) Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Histol Histopathol. 20(2):615-32.

Cassavaugh J, Lounsbury KM. (2011) Hypoxia-mediated biological control. J Cell Biochem. 112(3):735-44

Cervia D, Bagnoli P. (2007) An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther. 116(2):322-41.

Chao TC, Chao HH, Lin JD, Chen MF (1999) Somatostatin and octreotide modulate the function of Kupffer cells in liver cirrhosis. Regul Pept 79:117-124

Chen SH, Murphy DA, Lassoued W, Thurston G, Feldman MD, Lee WM (2008) Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 7:1994-2003

Chen Z, Htay A, Dos Santos W, Gillies GT, Fillmore HL, Sholley MM, Broaddus WC. (2009) *In vitro* angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells. J Neurooncol. 92(2):121-8.

Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, Zhang L, Han Z. (2008) Hemangiopoietin promotes endothelial cell proliferation through PI-3K/Akt pathway. Cell Physiol Biochem. ;22(1-4):307-14.

Chen Z, Han ZC (2008) STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28:185-200

Cho SW, Hartle L, Son SM, Yang F, Goldberg M, Xu Q, Langer R, Anderson DG (2008) Delivery of small interfering RNA for inhibition of endothelial cell apoptosis by hypoxia and serum deprivation. Biochem Biophys Res Commun 376:158-163

Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS, Park JW (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61:947-954

Cole SL, Schindler M. (2000) Characterisation of somatostatin sst2 receptor splice variants. J Physiol Paris. ;94(3-4):217-37.

Conway EM, Collen D, Carmeliet P. (2001) Molecular mechanisms of blood vessel growth. Cardiovasc Res. 49:507-21.

Cresci B, Giannini S, Pala L, Mavilia C, Manuelli C, Cappugi P, Maggi E, Rotella CM (2003) AT1 and AT2 receptors in human glomerular endothelial cells at different passages. Microvasc Res 66:22-29

Crocker DJ, Murad TM, Geer JC. (1970) Role of the pericyte in wound healing. An ultrastructural study. Exp Mol Pathol. 13(1):51-65.

Cucina A, Borrelli V, Randone B, Coluccia P, Sapienza P, Cavallaro A. (2003) Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells. J Surg Res.;109(1):16-23.

Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, Unnoura T, Iwakami S, Hirama M, Ishiwata T, Iwase A, Takahashi K (2009) Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 63:368-374

Cummins EP, Taylor CT (2005) Hypoxia-responsive transcription factors. Pflugers Arch 450:363-371

Curtis SB, Hewitt J, Yakubovitz S, Anzarut A, Hsiang YN, Buchan AM (2000) Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 278:H1815-H1822

Dal Monte M, Ristori C, Cammalleri M, Bagnoli P (2009) Effects of somatostatin analogues on retinal angiogenesis in a mouse model of oxygen-induced retinopathy: involvement of the somatostatin receptor subtype 2. Invest Ophthalmol Vis Sci 50:3596-3606

Dal Monte M, Ristori C, Videau C, Loudes C, Martini D, Casini G, Epelbaum J, Bagnoli P (2010) Expression, localization, and functional coupling of the somatostatin receptor subtype 2 in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 51:1848-1856

Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Del Tacca M (1997) Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 3:265-272

Dasgupta P (2004) Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102:61-85

DeNiro M, Alsmadi O, Al-Mohanna F (2009) Modulating the hypoxia-inducible factor signalling pathway as a therapeutic modality to regulate retinal angiogenesis. Exp Eye Res 89:700-717

Deudero JJ, Caramelo C, Castellanos MC, Neria F, Fernández-Sánchez R, Calabia O, Peñate S, González-Pacheco FR (2008) Induction of hypoxia-inducible factor 1alpha gene expression by vascular endothelial growth factor. J Biol Chem 283:11435-11444

Deudero JJ, Caramelo C, Castellanos MC, Neria F, Fernández-Sánchez R, Calabia O, Peñate S, González-Pacheco FR. (2008) Induction of hypoxia-inducible factor 1alpha gene expression by vascular endothelial growth factor. J Biol Chem. 283(17):11435-44.

Di Stefano R, Barsotti MC, Armani C, Santoni T, Lorenzet R, Balbarini A, Celi A (2009) Human peripheral blood endothelial progenitor cells synthesize and express functionally active tissue factor. Thromb Res 123:925-930

Drenkard D, Becke FM, Langstein J, Spruss T, Kunz-Schughart LA, Tan TE, Lim YC, Schwarz H (2007) CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J 21:456-463

Djonov V, Vacca A, Ria R, Ribatti D, Semeraro F, Di Raimondo F, Dammacco F. (2003) A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.Haematologica. 88(2):176-85.

Djonov V, Baum O, Burri PH. (2003) Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res.14:107-17.

Djonov V, Schmid M, Tschanz SA, Burri PH (2000) Intussusceptive angiogenesis: its role in embryonic vascular network formation. Circ Res. 86(3):286-92.

Dvorak HF, Brown LF, Detmar M, Dvorak AM. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146(5):1029-39.

Eltzschig HK, Köhler D, Eckle T, Kong T, Robson SC, Colgan SP (2009) Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 113:224-232

Epelbaum J, Dournaud P, Fodor M, Viollet C. (1994) The neurobiology of somatostatin. Crit Rev Neurobiol. 8(1-2):25-44.

Errico M, Riccioni T, Iyer S, Pisano C, Acharya KR, Persico MG, De Falco S. (2004). Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. J Biol Chem. 279:43929-39.

Feoktistov I, Ryzhov S, Zhong H, Goldstein AE, Matafonov A, Zeng D, Biaggioni I (2004) Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension 44:649-654

Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L, Susini C. Signal (2000) transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 94(3-4):205-10.

Ferrara N, Kowanetz M. (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 12(17):5018-22.

Ferrara N. (2001). Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 280:C1358-66

Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, Chisholm V, Hillan KJ, Schwall RH. (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med.4:336-40.

Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, Van Koetsveld PM, Mooy DM, Colao A, Minuto F, Lamberts SW,Hofland LJ. (2002) Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab. 283(5):E1056-66.

Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ (1999) Somatostatin activation of mitogenactivated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 13:24-37

Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A (2003) Somatostatin inhibits tumor angiogenesis and growth via somatostatin

receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 144:1574-1584

Folkman J, Ingber D. (1992) Inhibition of angiogenesis. Semin Cancer Biol. 3:89-96. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995 Jul 6;376(6535):66-70.

Fong GH. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med. 2009 Jun;87(6):549-60.

Gao G, Ma J. (2002) Tipping the balance for angiogenic disorders. Drug Discov Today. 7:171-2.

Gariboldi MB, Ravizza R, Monti E (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a prosurvival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80:455-462

George D. Yancopoulos, Samuel Davis, Nicholas W. Gale1, John S. Rudge, Stanley J. Wiegand & Jocelyn Holash (2000) progress Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248

Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 273(46):30336-43.

Gerber HP, Condorelli F, Park J, Ferrara N (1997) Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272:23659-23667

Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N. (2001) Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 276(5):3222-30.

Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE (2005) HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24:3110-3120

Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA. (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature.;456(7223):809-13.

Hannink M, Donoghue DJ. (1989) Structure and function of platelet-derived growth factor (PDGF) and related proteins. Biochim Biophys Acta. 989(1):1-10.

Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D (2002) Drug design at peptide receptors: somatostatin receptor ligands. J Mol Neurosci 18:15-27

Hashioka S, Klegeris A, Qing H, McGeer PL (2010) STAT3 inhibitors attenuate interferon-γ-induced neurotoxicity and inflammatory molecule production by human astrocytes. Neurobiol Dis

Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nistér M. (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52(11):3213-9.

Hicklin DJ, Ellis LM. (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23(5):1011-27.

Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M (1998) Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95:9349-9354

Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, Albertsson-Wikland K, Carlsson B, Niklasson A, Sjodell L, LeRoith D, Senger DR, Smith LE (2001). Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 98(10):5804-8.

Hellström M, Gerhardt H, Kalén M, Li X, Eriksson U, Wolburg H, Betsholtz C. (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 153(3):543-53.

Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. (1998). Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A.95:9349-54.

Hoeben A, Landuyt B, Highley M,Wildiers H, Van Oosterom A., De Bruijne E. (2004),Vascular Endothelial Growth Factor and Angiogenesis Pharmacological reviews 0031-6997/04/5604-549–580

Hofland LJ, Lamberts SW (2001) Somatostatin receptor subtype expression in human tumors. Ann Oncol 12 Suppl 2:S31-S36

Hofland LJ, van Hagen PM, Lamberts SW. (1999) Functional role of somatostatin receptors in neuroendocrine and immune cells. Ann Med. 31 Suppl 2:23-7.

Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, Hayakawa M, Sumitomo M, Asano T (2010) STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer 102:1592-1599

Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. (2000) Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest. 80(4):443-54.

Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 5(12):1806-14.

Hsu HK, Juan SH, Ho PY, Liang YC, Lin CH, Teng CM, Lee WS (2003) YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmacol 66:263-271

Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ (2002) Hypoxia enhances vascular cell proliferation and angiogenesis *in vitro* via rapamycin (mTOR)-dependent signaling. FASEB J16:771-780

Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y. (2002) Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16(2):219-21.

Jeong JK, Moon MH, Seo JS, Seol JW, Lee YJ, Park SY. (2011) Sulforaphane blocks hypoxia-mediated resistance to TRAIL-induced tumor cell death. Mol Med Report. 4(2):325-30.

Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. (2001). Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 15:1312-4.

Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, Wang J, Li JS, Zhai ZM, Xue Q (2003) Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 129:327-334

Jiang J, Xia XB, XU HZ, Xiong Ym, Song WT, Xiong SQ, Li Y (2009) Inhibition of Retinal Neovascularization by Gene Transfer of Small Interfering RNA Targeting HIF-1α and VEGF. J Cell Physiol 218: 66–74.

Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. (1997). Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 272:19253-60.

Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. (1996) A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J.;15(7):1751.

Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, Chung MH (2005) STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 19:1296-1298

Jung JE, Kim HS, Lee CS, Shin YJ, Kim YN, Kang GH, Kim TY, Juhnn YS, Kim SJ, Park JW, Ye SK, Chung MH (2008) STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp Mol Med 40:479-485

Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 92(8):3566-70.

Kaipainen A, Korhonen J, Pajusola K, Aprelikova O, Persico MG, Terman BI, Alitalo K. (1993) The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells. J Exp Med. 178(6):2077-88.

Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. (2004). Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 5:74-80.

Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. (2003). Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 93:1074-81.

Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. (1996) Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem. 271(10):5638-46.

Khaibullina AA, Rosenstein JM, Krum JM. (2004) Vascular endothelial growth factor promotes neurite maturation in primary CNS neuronal cultures. Brain Res Dev Brain Res. 148(1):59-68.

Kim JH, Park SH, Park SK, Choi JS, Xia Y, Sung JH (2011) The pivotal role of reactive oxygen species generation in the hypoxia-induced stimulation of adipose-derived stem cells. Stem Cells Dev.

Krantic S, Goddard I, Saveanu A, Giannetti N, Fombonne J, Cardoso A, Jaquet P, Enjalbert A. (2004) Novel modalities of somatostatin actions.Eur J Endocrinol. 151(6):643-55.

Krantic S. (2000) Peptides as regulators of the immune system: emphasis on somatostatin. Peptides. 21(12):1941-64.

Kroll J, Waltenberger J. (1999). A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem Biophys Res Commun. 265:636-9.

Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K. (1996) VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 122(12):3829-37.

Ladomery MR, Harper SJ, Bates DO. (2007). Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett. 249:133-42. Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-5.

Laemmli UK. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-5.

Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O (2008) Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Mol Cancer Ther 7:3509-3518

Lanneau C, Bluet-Pajot MT, Zizzari P, Csaba Z, Dournaud P, Helboe L, Hoyer D, Pellegrini E, Tannenbaum GS, Epelbaum J, Gardette R. (2000) Involvement of the Sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an *in vitro* and *in vivo* antisense study. Endocrinology. 141(3):967-79.

Lanner MC, Raper M, Pratt WM, Rhoades RA (2005) Heterotrimeric G proteins and the plateletderived growth factor receptor-beta contribute to hypoxic proliferation of smooth muscle cells. Am J Respir Cell Mol Biol 33:412-419

Lewin MJ. (1992) The somatostatin receptor in the GI tract. Annu Rev Physiol. 54:455-68.

Li M, Li W, Kim HJ, Yao Q, Chen C, Fisher WE (2004) Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 119:130-137

Lin CM, Shyu KG, Wang BW, Chang H, Chen YH, Chiu JH (2010) Chrysin suppresses IL-6-induced angiogenesis via down-regulation of JAK1/STAT3 and VEGF: an *in vitro* and *in vivo* approach. J Agric Food Chem 58:7082-7087

Lindahl P, Johansson BR, Levéen P, Betsholtz C. (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 277(5323):242-5.

Liu C, Dou K, Dou C, Liu J, Zhao Q (2010) Anti-inflammatory effects of tacrolimus in a rat model of acute pancreatitis. Med Chem 6:37-43

Liu S, Wu P, Ye D, Huang Y, Zhou X, Li Y, Cai L (2009) Effects of lipoxin A(4) on CoCl(2)-induced angiogenesis and its possible mechanisms in human umbilical vein endothelial cells. Pharmacology 84:17-23

Liu Y, Cox SR, Morita T, Kourembanas S. (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res.77:638-43.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408

Lohela M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21:154-165

Lohela M, Saaristo A, Veikkola T, Alitalo K. (2003). Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost. 90:167-84.

Lu W, Chen H, Yel F, Wang F, Xie X (2006) VEGF induces phosphorylation of STAT3 through binding VEGFR2 in ovarian carcinoma cells *in vitro*. Eur J Gynaecol Oncol 27:363-369

Luque A, Carpizo DR, Iruela-Arispe ML. (2003) ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem. 278(26):23656-65.

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, Compernolle V, Daci E, Bohlen P, Dewerchin M, Herbert JM, Fava R, Matthys P, Carmeliet G, Collen D, Dvorak HF, Hicklin DJ, Carmeliet P. (2002). Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 8:831-40.

Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H (2009) PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem 331:161-171

Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS (2005) *In vitro* procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 65(12):5365-73.

Mathews MT, Berk BC (2008) PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol 28:711-717

Mazzone M. (2010) Novel alternatives for anti-angiogenetic therapy and therapeutic angiogenesis. Verh K Acad Geneeskd Belg. 72(3-4):165-75.

Mechoulam H, Pierce EA. (2005) Expression and activation of STAT3 in ischemia-induced retinopathy.Invest Ophthalmol Vis Sci. 46(12):4409-16.

Melmed S, Vance ML, Barkan AL, Bengtsson BA, Kleinberg D, Klibanski A, Trainer PJ. (2002) Current status and future opportunities for controlling acromegaly. Pituitary. 5(3):185-96.

Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Büttner M, Rziha HJ, Dehio C. (1999). A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18:363-74

Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NP, Risau W, Ullrich A. (1993). High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell.72:835-46

Møller LN, Stidsen CE, Hartmann B, Holst JJ. (2003) Somatostatin receptors. Biochim Biophys Acta. 1616(1):1-84.

Mousa SA, Lorelli W, Campochiaro PA. (1999) Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem.74:135-43.

Msaouel P, Galanis E, Koutsilieris M. (2009) Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs. 18(9):1297-316.

Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C (2006) Adipokine resistin promotes *in vitro* angiogenesis of human endothelial cells. Cardiovasc Res 70:146-157

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J.13:9-22.

Nilsson I, Shibuya M, Wennström S (2004) Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 299:476-485

Nussenbaum F, Herman IM (2010) Tumor Angiogenesis: Insights and Innovations. J Oncol 2010:132641

Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, Failla CM, Zambruno G. (2002). Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci.115:2559-67.

Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, Orpana A, Pettersson RF, Alitalo K, Eriksson U. (1996). Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A. 93:2576-81.

Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W (2004) Regulation and function of somatostatin receptors. J Neurochem 89:1057-1091

Oomen SP, Ward AC, Hofland LJ, Lamberts SW, Lowenberg B, Touw IP (2001) Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2. Hematol J 2:322–329

Ootsuka S, Asami S, Sasaki T, Yoshida Y, Nemoto N, Shichino H, Chin M, Mugishima H, Suzuki T (2007) Analyses of novel prognostic factors in neuroblastoma patients. Biol Pharm Bull 30:2294-2299

Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA. (1999). Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 40:182-9.

Pagès G, Pouysségur J. (2005). Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res. 65:564-73.

Palii SS, Afzal A, Shaw LC, Pan H, Caballero S, Miller RC, Jurczyk S, Reubi JC, Tan Y, Hochhaus G, Edelhauser H, Geroski D, Shapiro G, Grant MB (2008) Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor. Invest Ophthalmol Vis Sci 49:5094-5102

Park SJ, Kim HY, Kim H, Park SM, Joe EH, Jou I, Choi YH (2009) Oxidative stress induces lipidraft-mediated activation of Src homology 2 domain-containing protein-tyrosine phosphatase 2 in astrocytes. Free Radic Biol Med 46:1694-1702

Patan S. (2004) Vasculogenesis and angiogenesis. Cancer Treat Res. 117:3-32.

Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. (1999) 20(3):157-98.

Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME, Haber E (1996). Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 98:490-496

Pearlstein DP, Ali MH, Mungai PT, Hynes KL, Gewertz BL, Schumacker PT (2002). Role of mitochondrial oxidant generation in endothelial cell responses to hypoxia. Arterioscler Thromb Vasc Biol 22:566-573

Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest.72:638-45.

Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. (2000) Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 95(3):952-8.

Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. (2008). Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 27:331-71

Perez J, Viollet C, Doublier S, Videau C, Epelbaum J, Baud L (2003) Somatostatin binds to murine macrophages through two distinct subsets of receptors. J Neuroimmunol 138:38-44

Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM (2002) Characterization of the human somatostatin receptor type 4 promoter. Mol Cell Endocrinol 188:75-83

Pietras K, Ostman A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH and Rubin K (2001): Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934.

Regnault TR, Orbus RJ, de Vrijer B, Davidsen ML, Galan HL, Wilkening RB, Anthony RV. (2002) Placental expression of VEGF, PlGF and their receptors in a model of placental insufficiency-intrauterine growth restriction (PI-IUGR). Placenta. 23(2-3):132-44.

Reinmuth N, Liersch R, Raedel M, Fehrmann F, Fehrmann N, Bayer M, Schwoeppe C, Kessler T, Berdel W, Thomas M, Mesters RM (2009) Combined anti-PDGFRalpha and PDGFRbeta targeting in non-small cell lung cancer. Int J Cancer 124:1535-1544

Reubi JC, Horisberger U, Laissue J (1994) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer 56:681-688

Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836-846

Risau W, Flamme I. (1995) Vasculogenesis. Annu Rev Cell Dev Biol. 11:73-91.

Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K and Heldin CH (1992): Platelet-derived growth factor is angiogenic *in vivo*. Growth Factors 7: 261-266,

Robinson CJ, Stringer SE. (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 114(Pt 5):853-65.

Rocha A, Azevedo I, Soares R (2007) Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. Angiogenesis 10:279-286

Ruffini F, Failla CM, Orecchia A, Bani MR, Dorio AS, Fortes C, Zambruno G, Graziani G, Giavazzi R, D'Atri S, Lacal PM. (2010) Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumor progression. Br J Dermatol.

Ruiter DJ, Schlingemann RO, Westphal JR, Denijn M, Rietveld FJ, De Waal RM(1993). Angiogenesis in wound healing and tumor metastasis. Behring Inst Mitt. (92):258-72.

Saaristo A, Partanen TA, Arola J, Jussila L, Hytönen M, Mäkitie A, Vento S, Kaipainen A, Malmberg H, Alitalo K. (2000). Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. Am J Pathol. 157:7-14.

Sarkanen JR, Mannerström M, Vuorenpää H, Uotila J, Ylikomi T, Heinonen T (2011). Intra-Laboratory Pre-Validation of a Human Cell Based *in vitro* Angiogenesis Assay for Testing Angiogenesis Modulators. Front Pharmacol doi: 10.3389/fphar.

Schenone S, Manetti F, Botta M. (2007) SRC inhibitors and angiogenesis. Curr Pharm Des. 13(21):2118-28.

Schenone S, Bondavalli F, Botta M. (2007) Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Curr Med Chem.14(23):2495-516.

Schneider C, Krischke G, Keller S, Walkinshaw G, Arend M, Rascher W, Gassmann M, Trollmann R. (2009). Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain.. Brain Res. 1280:43-51.

Schulz S, Händel M, Schreff M, Schmidt H, Höllt V. (2000) Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies. J Physiol Paris. 94(3-4):259-64.

Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. (1995) A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 10(1):135-47.

Semenza GL. (2004). Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology (Bethesda).19:176-82.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983-5.

Shen BQ, Lee DY, Zioncheck TF. (1999). Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem.274:33057-63.

Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312:549-560

Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104:7391-7396

Siemann DW, Horsman MR. (2009) Vascular targeted therapies in oncology. Cell Tissue Res. 335(1):241-8.

Siemann DW, Brazelle WD, (2009) Jürgensmeier JM. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. Int J Radiat Oncol Biol Phys. 73(3):897-903.

Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagsbrun M. (1997) Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem. 272(50):31582-8.

Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 7:186-91.

Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK (1996) Flk-1 as a target for tumor growth inhibition. Cancer Res 56:3540-3545

Suyun Huang (2007) Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications Clin Cancer Res; 13:1362-1366.

Takahashi H, Shibuya M. (2009). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 109:227-41.

Takahashi H, Shibuya M. (2005). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 109:227-41.

Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, Yin L, Ohta T, Kawagoe J, Takahashi K, Kurachi H (2008) Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 7:1551-1561

Tanaka S, Arii S (2006) Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol 11:82-89

Thakker GD, Hajjar DP, Muller WA, Rosengart TK. (1999) The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem. 274(15):10002-7.

Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P. (1992). Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun.187:1579-86.

Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 266(18):11947-54.

Thommen R, Humar R, Misevic G, Pepper MS, Hahn AW, John M and Battegay EJ (1997): PDGF-BB increases endothelial migration on cord movements during angiogenesis *in vitro*. J Cell Biochem 64: 403-413,

Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. *In vivo* activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J. 2002 Feb;16(2):225-7.

Valtola R, Salven P, Heikkilä P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K. (1999). VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 154:1381-90.

Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K.(2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:203-12.

Waltenberger J, Mayr U, Pentz S, Hombach V (1996) Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 94:1647-1654

Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 269(43):26988-95.

Wang M, Tan J, Coffey A, Fehrenbacher J, Weil BR, Meldrum DR (2009) Signal transducer and activator of transcription 3-stimulated hypoxia inducible factor-1alpha mediates estrogen receptoralpha-induced mesenchymal stem cell vascular endothelial growth factor production. J Thorac Cardiovasc Surg 138:163-171

Watanabe D, Takagi H, Suzuma K, Oh H, Ohashi H, Honda Y. (2005) Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina. 25(7):911-8.

Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, Drouant GJ, Woltering EA (2001) Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 85:266-272

Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017

Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K. (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 22(3):319-29.

Woltering EA (2003) Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 18:601-609

Wyler von Ballmoos M, Yang Z, Völzmann J, Baumgartner I, Kalka C, Di Santo S (2010) Endothelial progenitor cells induce a phenotype shift in differentiated endothelial cells towards PDGF/PDGFRβ axis-mediated angiogenesis. PLoS One 5:e14107

Xu Q, Ji YS, Schmedtje JF Jr (2000) Sp1 increases expression of cyclooxygenase-2 in hypoxicvascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure. J Biol Chem 275:24583-24589

Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552-5560

Xu Houa, Anil Kumara, Chunsik Leea, Bin Wangc, Pachiappan Arjunana, Lijin Donga, Arvydas Maminishkisa, Zhongshu Tanga, Yang Lia, Fan Zhanga, Shi-Zhuang Zhangc, Piotr Wardegad, Sagarika Chakrabartya, Baoying Liua, Zhijian Wua, Peter Colosia, Robert N. Farissa, Johan Lennartssond, Robert Nussenblatta, J. Silvio Gutkinde, Yihai Caof, and Xuri Lia, (2010) 1 PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets Proc Natl Acad Sci USA 107(27):12216-21

Yang XP, Irani K, Mattagajasingh S, Dipaula A, Khanday F, Ozaki M, Fox-Talbot K, Baldwin WM 3rd, Becker LC (2005) Signal transducer and activator of transcription 3alpha and specificity protein 1 interact to upregulate intercellular adhesion molecule-1 in ischemic-reperfused myocardium and vascular endothelium. Arterioscler Thromb Vasc Biol 25:1395-1400

Yonemori K, Tsuta K, Ando M, Hirakawa A, Hatanaka Y, Matsuno Y, Chuman H, Yamazaki N, Fujiwara Y, Hasegawa T. (2011) Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor-β and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma. Ann Surg Oncol.

Yoshie M, Miyajima E, Kyo S, Tamura K (2009) Stathmin, a microtubule regulatory protein, is associated with hypoxia-inducible factor-1alpha levels in human endometrial and endothelial cells. Endocrinology 150:2413-2418

Zachary I, Gliki G. (2001) Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor familyCardiovasc Res. 49(3):568-81.

Zammaretti P, Zisch AH. Adult 'endothelial progenitor cells'. Renewing vasculature. Int J Biochem Cell Biol. 2005 37(3):493-503.

Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in nonfunctioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion Endocr Relat Cancer 14:91-102

Zeng H, Dvorak HF, Mukhopadhyay D (2001) Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276:26969-26979

Zhang SS, Wei JY, Li C, Barnstable CJ, Fu XY (2003). Expression and activation of STAT proteins during mouse retina development. Exp Eye Res. 76(4):421-31.

Zhang Y, Stone J. (1997). Role of astrocytes in the control of developing retinal vessels. Invest Ophthalmol Vis Sci. 38:1653-66.

Zhang X, Ling MT, Feng H, Wong YC, Tsao SW, Wang X. (2004) Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells. Br J Cancer. 91(12):2042-7.

Zheng X, Zhang S, Yang Y, Wang X, Zhong L, Yu X (2008) The targeting expression of the vascular endothelial growth factor gene in endothelial cells regulated by HRE.ppET-1. Sci China C Life Sci 51:959-965

Zhong XS, Zheng JZ, Reed E, Jiang BH (2004) SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 324:471-480

Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. (1997). Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 99:2625-34.